5-(N,N-dimethyl)-Amiloride (hydrochloride): A Benchmark NHE1 Inhibitor for Cardiovascular and Endothelial Research

Executive Summary: 5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA) selectively inhibits Na+/H+ exchanger (NHE) isoforms NHE1, NHE2, and NHE3, with nanomolar to micromolar Ki values, supporting precise intracellular pH regulation (Chen et al., 2021). The compound demonstrates efficacy in protecting cardiac tissue against ischemia-reperfusion injury by stabilizing sodium homeostasis. DMA’s selectivity profile minimizes off-target effects on other NHE isoforms. Its validated use extends to studies of endothelial injury, sodium-potassium ATPase activity, and amino acid transport in hepatocytes. APExBIO’s C3505 product is optimized for research reliability and reproducibility (APExBIO).

Biological Rationale

The Na+/H+ exchanger (NHE) family consists of membrane proteins that regulate intracellular pH and cell volume by extruding protons in exchange for sodium ions. NHE1 is ubiquitously expressed in mammalian cells and is critical for maintaining intracellular pH homeostasis, especially in cardiac and endothelial tissues (Chen et al., 2021). Dysregulation of NHE1 activity contributes to pathological processes such as ischemia-reperfusion injury, sepsis-induced endothelial dysfunction, and cardiovascular disease. Inhibitors targeting NHE1, such as 5-(N,N-dimethyl)-Amiloride (hydrochloride), allow researchers to dissect ion transport mechanisms and pH regulation with high specificity. Recent research highlights the role of NHE1 and associated proteins (e.g., moesin) in modulating vascular permeability and inflammatory signaling during acute organ injury (Chen et al., 2021).

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA is a crystalline solid derivative of amiloride. It acts as a potent and selective inhibitor of NHE1 (Ki = 0.02 μM), NHE2 (Ki = 0.25 μM), and NHE3 (Ki = 14 μM), with negligible activity on NHE4, NHE5, and NHE7 (APExBIO). By blocking the Na+/H+ exchanger, DMA prevents sodium influx and proton extrusion, leading to controlled intracellular acidification and reduced sodium accumulation. This action is particularly relevant in cardiac and endothelial cells, where NHE1-mediated sodium entry can exacerbate injury during hypoxic or inflammatory conditions. DMA also inhibits ouabain-sensitive ATP hydrolysis and Na+/K+ ATPase activity in rat liver plasma membranes, and it decreases alanine uptake in hepatocytes, indicating broader effects on ion and solute transport (APExBIO).

Evidence & Benchmarks

• DMA inhibits NHE1 with a Ki of 0.02 μM, supporting high-affinity and selective blockade of Na+/H+ exchange in mammalian cells (APExBIO).
• NHE1 inhibition by DMA normalizes tissue sodium levels and protects against contractile dysfunction in cardiac ischemia-reperfusion models (Chen et al., 2021).
• DMA shows minimal inhibition of NHE4, NHE5, and NHE7, reducing risk of off-target effects in experimental systems (APExBIO).
• DMA inhibits ouabain-sensitive ATP hydrolysis and Na+/K+ ATPase activity in rat liver plasma membranes (APExBIO).
• DMA reduces alanine uptake in hepatocytes, demonstrating effects on amino acid transport and cell metabolism (APExBIO).
• Activation of NHE1 and associated cytoskeletal proteins (e.g., moesin) is linked to increased endothelial permeability and inflammation during sepsis (Chen et al., 2021).

This article extends the mechanistic discussion in "5-(N,N-dimethyl)-Amiloride Hydrochloride: Deep Mechanisti..." by providing explicit benchmark data and comparative selectivity profiles for DMA.

For a translational perspective, see "5-(N,N-dimethyl)-Amiloride Hydrochloride: Unveiling New F...", which connects NHE1 inhibition to clinical models in sepsis and cardiac research, whereas the current article focuses on atomic, quantitative research details.

Applications, Limits & Misconceptions

5-(N,N-dimethyl)-Amiloride (hydrochloride) enables highly specific studies of Na+/H+ exchanger signaling, intracellular pH homeostasis, and sodium ion transport in cardiovascular, hepatic, and endothelial injury models. It is particularly valuable for dissecting the molecular mechanisms underlying ischemia-reperfusion injury and sepsis-induced endothelial dysfunction. DMA's selectivity for NHE1 provides a reliable tool for modulating sodium and proton fluxes without significant off-target inhibition of other exchanger isoforms. However, users should be aware of methodological and interpretive boundaries.

Common Pitfalls or Misconceptions

• DMA does not efficiently inhibit NHE4, NHE5, or NHE7; results in tissues expressing these isoforms may not reflect true NHE1-dependent effects (APExBIO).
• DMA is not recommended for diagnostic or clinical therapeutic use; it is intended strictly for research applications (APExBIO).
• Long-term storage of DMA solutions, even at -20°C, leads to degradation; fresh solutions are necessary for reproducible results (APExBIO).
• DMA may affect additional ion transporters at high concentrations; always titrate to minimal effective dose for specificity.
• Cell-type specific differences in NHE isoform expression may necessitate parallel controls using genetic or alternative pharmacological tools.

For a broader context on benchmarking and translational impact, see "5-(N,N-dimethyl)-Amiloride (hydrochloride): Benchmarking ...", which summarizes use-cases and validation in cardiovascular and endothelial research; this article clarifies selectivity and kinetic parameters for rigorous experimental planning.

Workflow Integration & Parameters

APExBIO’s 5-(N,N-dimethyl)-Amiloride (hydrochloride) (C3505) is supplied as a crystalline solid, soluble up to 30 mg/ml in DMSO and dimethyl formamide (APExBIO). For typical in vitro applications, stock solutions are prepared fresh in DMSO and diluted into physiological buffers immediately before use. Recommended storage is at -20°C. Repeated freeze-thaw cycles and prolonged storage of working solutions are discouraged. Dose-response experiments in NHE1-dependent cell types often start at 0.01–1 μM concentrations, with titration based on cell viability and pH readouts. DMA’s high selectivity supports use in primary cardiomyocytes, endothelial monolayers, and hepatocyte models. Controls should include vehicle and, where feasible, genetic knockdown or alternative NHE inhibitors to confirm specificity.

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride (hydrochloride) is a validated, potent, and selective NHE1 inhibitor that enables atomic-level dissection of Na+/H+ exchanger function in cardiovascular and endothelial research. Its robust performance in controlling intracellular pH and sodium homeostasis underpins research into ischemia-reperfusion injury, endothelial dysfunction, and related pathologies. APExBIO’s C3505 product is a reference standard for experimental rigor in this domain. Ongoing research into NHE1 and related pathways will further elucidate the translational relevance of DMA-based interventions in cardiovascular disease and sepsis (Chen et al., 2021). Researchers should consult the product documentation for the latest handling and application guidelines.